Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Alios BioPharma
South San Francisco, California, United States
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Alios BioPharma developed AL-8176, an orally administered antiviral therapy for RSV that showed promising results in Phase 2 studies. In clinical trials, volunteers infected with RSV showed no symptoms within a day and a half of receiving the drug and completely lost the virus, while the placebo group had persistent virus and symptoms for several days.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Nucleoside analogsAntiviral therapeutics
- Industry
- Biotech
02
Partnerships
Vertex PharmaceuticalsJanssen Pharmaceutical Companies of Johnson & Johnson
Beyond the preview
Go deeper on Alios BioPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alios BioPharma.